MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of FDA-approved CAR-T products for patients with hematologic
malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall
remission rate, safety events and other endpoints will be calculated for Arm A and B
separately.